This indicates a vast improvement in outcomes for those patients after implementation of durvalumab maintenance, considering IO was almost exclusively administered in patients with PD-L1 on ≥ 1% of tumor cells due to regulations by the European medicines agency (EMA). Here, CD274 is linked to neoplasm.